Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugation
Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugation
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Pancreatic adenocarcinoma (PAAD) is highly challenging to treat due to its poor prognosis and limited effective treatment options. Liposomal nanotechnology has emerged as a promising drug delivery platform in oncology, but existing liposomal therapies face limitations such as systemic toxicity, insufficient tumor selectivity, and low target specifi...
Alternative Titles
Full title
Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugation
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_7e6e0ba5f5134759b09d1ec2dd410ed4
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7e6e0ba5f5134759b09d1ec2dd410ed4
Other Identifiers
ISSN
1476-4598
E-ISSN
1476-4598
DOI
10.1186/s12943-025-02325-7
